Filter posts

Patients Suffering from Gaucher's Disease Deserve Better

Gaucher Disease is one of the over 6,000 rare diseases that affect patients worldwide, representing …

BIO Participating in IDSA Stakeholder Group on Antimicrobial Resistance

BIO will be participating in a newly formed partnership which will work collaboratively to inform …

BIO Submits Amicus Briefs in Braintree v. Novel, Gilead v. Natco, and Bristol-Myers Squibb v. Teva P...

BIO has submitted briefs in three recent cases which could significantly impair drug and biotechnology …

PTO Patent Examinations in the wake of Mayo and Myriad

Biotech patent applicants are finding themselves in uncharted waters.   After the Supreme Court’s decisions …

Forbes: Faster FDA Approvals Have Not Caused More Drug Safety Problems

In 1992, Congress, industry, and the FDA worked together to create the Prescription Drug User Fee …

Delivering on Biotech’s Promise to Treat Anthrax, Smallpox, Ebola

Thanks to federal biodefense programs that partner with industry to develop and stockpile medical countermeasures, …

BIO Submits Comments on “Myriad” PTO Patent Guidance

On July 31st, BIO, alongside a group of international bioindustry trade associations submitted comments to …

Partners for Healthy Dialogues: Letter to CMS

BIO, a member of Partners for Healthy Dialogues (P4HD), joined 25 medical societies and manufacturers in …

New Report: Innovation in Hepatitis C Treatment

Today, the California Healthcare Institute released a report on the public health impact of Hepatitis …

What International Trade Agreements Have to Do with Innovation

Innovation is not just the life-blood of the biotech industry, it is the very premise …